BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 77.56 USD | +0.77% |
|
-4.28% | -19.56% |
Presenter SpeechTraci McCarty (Executives)Please go ahead, JJ. ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
21/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
77.56
USD
Average target price
109.3
USD
Spread / Average Target
+40.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.56% | 14.73B | |
| -2.32% | 90.45B | |
| +3.68% | 41.45B | |
| -10.90% | 33.57B | |
| +58.05% | 25.73B | |
| -9.06% | 12.82B | |
| -11.34% | 11.7B | |
| -43.53% | 11.44B | |
| +3.75% | 8.79B | |
| -6.32% | 8.35B |
- Stock Market
- Equities
- BMRN Stock
- News BioMarin Pharmaceutical Inc.
- Transcript : BioMarin Pharmaceutical Inc. - Special Call
